V good summary about LDX + future potential + key competitors (+ AT1 is mentioned towards the end as device supplier). Not much new info but its detailed enough nevertheless for anyone that hasn't read all the IPO docs.
End summary is good as it (correctly) details the far larger, more lucrative, post-Covid19 market for antibiotic resistance testing.
Final line sums up LDX biz potential + risks nicely: "With the pandemic still raging it’s a case of so far, SAR(s) good for Lumos in its early life on the ASX stage but expanding its songbook would be desirable."
LDX Price at posting:
$1.25 Sentiment: Buy Disclosure: Not Held
